{"filing":{"accession_number":"0001193125-26-336462","cik":"0002100782","ticker":"GENB","company_name":"Generate Biomedicines, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ck0002100782-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-20260806.htm"},"events":[{"id":25504,"run_id":23146,"accession_number":"0001193125-26-336462","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Generate Biomedicines issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, including revenue of $6.3 million, R\u0026D expenses of $64.3 million, net loss of $67.3 million, and cash position of $457.4 million. The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which are hallmarks of a quarterly earnings release under Item 2.02.","company_name":"Generate Biomedicines, Inc.","ticker":"GENB","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26346,"accession_number":"0001193125-26-336462","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Generate Biomedicines issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, including revenue of $6.3 million, R\u0026D expenses of $64.3 million, net loss of $67.3 million, and cash position of $457.4 million. The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which are hallmarks of a quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:54.956916+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26346,"accession_number":"0001193125-26-336462","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Generate Biomedicines issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, including revenue of $6.3 million, R\u0026D expenses of $64.3 million, net loss of $67.3 million, and cash position of $457.4 million. The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which are hallmarks of a quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:54.956916+00:00","company_name":"Generate Biomedicines, Inc.","ticker":"GENB","filing_date":"2026-08-06"}]}